Sage Therapeutics SAGE 深 沪
已收盘 07-31 16:00:00 美东时间
8.68
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.68
- 总市值 5.44亿
- 52周最高 9.36
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.62
- 委 比 0.00%
- 总股本 6262.23万
- 历史最高 195.97
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.62
- 每 手 1
- 风险率 1.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Supernus Pharmaceuticals Clears Antitrust Hurdle For Sage Therapeutics Acquisition In $8.50/Share Cash Offer Plus Up To $3.50/Share In Contingent Value Rights Merger
Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supern
07-28 20:27
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
Supernus Pharmaceuticals announced the expiration of the Hart-Scott-Rodino Act waiting period for its proposed acquisition of Sage Therapeutics. The $8.50 cash offer plus a contingent value right (CVR) for Sage's shares remains subject to certain conditions. The CVR includes potential payments tied to regulatory milestones and U.S. sales targets for ZURZUVAE, with total potential value up to $3.50 per share. The tender offer expires July 30, 2025...
07-28 12:25
KalVista, Biogen, Ionis get EU positive opinions for key drugs
KalVista Pharmaceuticals (NASDAQ:KALV), Biogen (NASDAQ:BIIB), and Ionis Pharmaceuticals (NASDAQ:IONS) announced that the European Medicines Agency (EMA) has given positive endorsements for their produ...
07-25 21:23
华硕TRX50主板首秀 多款ProArt、WS主板赋能BIRTV2025
【7/23/2025,新闻稿，共6页】 华硕TRX50主板首秀多款ProArt、WS主板赋能BIRTV2025备选：算力重构视界华硕主板惊艳BIRTV2025...
07-24 17:39
ZyVersa Therapeutics Releases Mid-Year Shareholder Letter Highlighting Recent Corporate Developments And R&D Progress Including Closing Two Financial Transactions Providing Access To $12M In Capital
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have
07-21 20:04
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock
6 analysts have expressed a variety of opinions on Sage Therapeutics (NASDAQ:SA...
07-08 22:00
Scotiabank Downgrades Sage Therapeutics to Sector Perform, Lowers Price Target to $9.2
Scotiabank analyst George Farmer downgrades Sage Therapeutics (NASDAQ:SAGE) from Sector Outperform to Sector Perform and lowers the price target from $12 to $9.2.
07-08 20:26
Sage Potash Raises C$6 Million to Advance Utah Project
Sage Potash Corp. ( ($TSE:SAGE) ) has shared an announcement. Sage Potash Corp....
06-27 08:37
